Appointments Jobs About Search Education & Research Clinical Trials Health Information Medical Services

Publications - Chunhee R . Choo, M.D.

Back to Research Profile

  1. Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P, Pearse M. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse. Int J Radiat Oncol Biol Phys 2009 Nov 15; 75(4):983-9. Epub 2009 May 04.
    View PubMed
  2. Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P, Pearse M. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins. Int J Radiat Oncol Biol Phys 2009 Oct 1; 75(2):407-12. Epub 2009 Feb 11.
    View PubMed
  3. Choo R, Long J, Gray R, Morton G, Gardner S, Danjoux C. Prospective survey of sexual function among patients with clinically localized prostate cancer referred for definitive radiotherapy and the impact of radiotherapy on sexual function. Support Care Cancer 2009 Jun 09. [Epub ahead of print]
    View PubMed
  4. Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Andrew Loblaw D, Cheung P, Pearse M. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with psa relapse. Int J Radiat Oncol Biol Phys 2009 Apr 29. [Epub ahead of print]
    View PubMed
  5. Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw A, Cheung P, Pearse M. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse. Int J Rad Onc Biol Phys 2009 Apr 29. [Epub ahead of print]
    View PubMed
  6. Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Andrew Loblaw D, Cheung P, Pearse M. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with psa relapse. Int J Radiat Oncol Biol Phys 2009 Apr 29. [Epub ahead of print]
    View PubMed
  7. Pisansky TM, Gold DG, Furutani KM, Macdonald OK, McLaren RH, Mynderse LA, Wilson TM, Hebl JR, Choo R. High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer. Mayo Clin Proc 2008 Dec; 83(12):1364-72.
    View PubMed
  8. Choo R, Pearse M, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P. Analysis of gastrointestinal and genitourinary morbidity of postoperative radiotherapy for pathologic T3 disease or positive surgical margins after radical prostatectomy using national cancer institute expanded common toxicity criteria. Int J Radiat Oncol Biol Phys 2008 Nov 15; 72(4):989-95. Epub 2008 Apr 23.
    View PubMed
  9. Pearse M, Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw A, Cheung P. Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 2008 Nov 1; 72(3):792-8. Epub 2008 Aug 15.
    View PubMed
  10. Pearse M, Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Lorlaw A, Cheung P. Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 2008 Nov 1; 72(3):792-8 Epub 2008 Aug 15.
    View PubMed
  11. Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. J Urol 2008 Oct; 180(4):1438-43; discussion 1443-4. Epub 2008 Aug 16.
    View PubMed
  12. Lim TS, Cheung PC, Loblaw DA, Morton G, Sixel KE, Pang G, Basran P, Zhang L, Tirona R, Szumacher E, Danjoux C, Choo R, Thomas G. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results. Int J Radiat Oncol Biol Phys 2008 Sep 1; 72(1):85-92. Epub 2008 Mar 20.
    View PubMed
  13. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovacs A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS, International Breast Cancer S Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. J Clin Oncol 2008 Mar 20; 26(9):1404-10.
    View PubMed
  14. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovacs A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS, International Breast Cancer S Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. J Clin Oncol 2008 Mar 20; 26(9):1404-10.
    View PubMed
  15. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS, other collaborators (inc Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. J Clin Oncol. 2008; 26:1404-1410.
    View PubMed
  16. Yoon FH*, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R. Testosterone recovery after prolonged androgen suppression in prostate cancer patients. J Urol. 2008; 180:1438-1443.
    View PubMed
  17. Pearse M*, Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw A, Cheung P. Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with PSA relapse or local recurrence after radical prostatectomy. Int J Rad Onc Biol Phys. 2008; 72:792-798.
    View PubMed
  18. Choo R, Pearce A, Danjoux C, Morton G, Deboer G, Szumacher E, Loblaw A, Cheung P. Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy. Eur Urol 2007 Dec; 52(6):1645-50. Epub 2006 Nov 15.
    View PubMed
  19. Choo R, Danjoux C, Morton G, Szumacher E, Sugar L, Gardner S, Kim M, Choo CM, Klotz L. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer? Prostate 2007 Nov 1; 67(15):1614-20.
    View PubMed
  20. Schwartz DJ, Sengupta S, Hillman DW, Sargent DJ, Cheville JC, Wilson TM, Mynderse LA, Choo R, Davis BJ. Prediction of radial distance of extraprostatic extension from pretherapy factors. Int J Radiat Oncol Biol Phys 2007 Oct 1; 69(2):411-8.
    View PubMed
  21. Choo R, Kawakami J, Siemens R, Davis BJ, Brundage M, Pisansky TM. Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy. BJU Int 2006 Oct; 98(4):773-6.
    View PubMed
  22. Vieth R, Choo R, Deboer L, Danjoux C, Morton GC, Klotz L. Rise in prostate-specific antigen in men with untreated low-grade prostate cancer is slower during spring-summer. Am J Ther 2006 Sep-Oct; 13(5):394-9.
    View PubMed
  23. Pearce A, Choo R, Danjoux C, Morton G, Loblaw DA, Szumacher E, Cheung P, Deboer G, Chander S. Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys 2006 May 1; 65(1):78-83. Epub 2006 Mar 24.
    View PubMed
  24. Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005 Sep 1; 23(25):6132-8.
    View PubMed
  25. Choo R, Woo T, Assaad D, Antonyshyn O, Barnes EA, McKenzie D, Fialkov J, Breen D, Mamedov A. What is the microscopic tumor extent beyond clinically delineated gross tumor boundary in nonmelanoma skin cancers? Int J Radiat Oncol Biol Phys 2005 Jul 15; 62(4):1096-9.
    View PubMed
  26. Chander S, Choo R, Danjoux C, Morton G, Pearse A, Deboer G, Szumacher E, Loblaw A, Cheung P, Woo T. Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery. Int J Radiat Oncol Biol Phys 2005 Jul 1; 62(3):719-24.
    View PubMed
  27. Cheung P, Sixel K, Morton G, Loblaw DA, Tirona R, Pang G, Choo R, Szumacher E, Deboer G, Pignol JP. Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer. Int J Radiat Oncol Biol Phys 2005 Jun 1; 62(2):418-25.
    View PubMed
  28. Choo R, Thomas G, Woo T, Lee D, Kong B, Iscoe N, Danjoux C, Klotz L, Morton G, Chander S. Long-term outcome of postorchiectomy surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2005 Mar 1; 61(3):736-40.
    View PubMed
  29. Choo R, Morton G, Danjoux C, Hong E, Szumacher E, DeBoer G. Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate, carcinoma after surgery. Radiother Oncol 2005 Feb; 74(2):163-7.
    View PubMed
  30. Choo R, Chander S, Danjoux C, Morton G, Pearse A, DeBoer G, Szumacher E, Loblaw A, Cheung P, Woo T. How are hemoglobin levels affected by androgen suppression in non-metastatic prostate cancer patients? Can J Urol. 2005; 12:2547-2552.
    View PubMed
  31. Woo TC, Choo R, Jamieson M, Chander S, Vieth R. Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer 2005; 51(1):32-6.
    View PubMed
  32. Woo TC, Choo R, Chander S. An unusual case of concurrent breast and prostate cancer. Can J Urol 2004 Oct; 11(5):2390-2.
    View PubMed
  33. Choo R, Klotz L, Deboer G, Danjoux C, Morton GC. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU Int 2004 Aug; 94(3):295-8.
    View PubMed
  34. Bagnell S, Choo R, Klotz LH, Chaterjee S. Practice patterns of Canadian urologists in the management of stage I testicular seminoma. Can J Urol 2004 Apr; 11(2):2194-9.
    View PubMed
  35. Choo R, Do V, Sugar L, Klotz L, Bahk E, Hong E, Danjoux C, Morton G, DeBoer G. Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer. Can J Urol 2004 Feb; 11(1):2118-24.
    View PubMed
  36. Choo R, Sugar L, Hong E, Mackenzie K, DeBoer G, Danjoux C, Morton G, Klotz L. Is there a progression of histologic grade from radical prostatectomy to local recurrence in patients with clinically isolated local recurrence following surgery? Can J Urol 2003 Oct; 10(5):1981-5.
    View PubMed
  37. Yap BK, Choo R, Deboer G, Klotz L, Danjoux C, Morton G. Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade prostate cancer managed with watchful observation alone? BJU Int 2003 May; 91(7):613-7.
    View PubMed
  38. Bunting PS, DeBoer G, Choo R, Danjoux C, Klotz L, Fleshner N. Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clin Biochem 2002 Sep; 35(6):471-5.
    View PubMed
  39. Hruby G, Choo R, Jackson M, Warde P, Sandler H. Management preferences following radical inguinal orchidectomy for Stage I testicular seminoma in Australasia. Australas Radiol 2002 Sep; 46(3):280-4.
    View PubMed
  40. Do V, Choo R, Deboer G, Herschorn S, Danjoux C, Chen CH, Barak I. Urodynamic findings 3 months after radiotherapy in patients treated with conformal external beam radiotherapy for prostate carcinoma. BJU Int 2002 Jul; 90(1):62-7.
    View PubMed
  41. Choo R, Hruby G, Hong J, Bahk E, Hong E, Danjoux C, Morton G, DeBoer G. (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 2002 Jun 1; 53(2):269-76.
    View PubMed
  42. Choo R, Do V, Herschorn S, DeBoer G, Danjoux C, Morton G, Cheng CH, Barak I, Preiner J. Urodynamic changes at 18 months post-therapy in patients treated with external beam radiotherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2002 Jun 1; 53(2):290-6.
    View PubMed
  43. Klotz LH, Choo R, Morton G, Danjoux C. Expectant management with selective delayed intervention for favorable-risk prostate cancer. Can J Urol 2002 Jun; 9 Suppl 1:2-7.
    View PubMed
  44. Do V, Choo R, De Boer G, Klotz L, Danjoux C, Morton G, Szumacher E, Fleshner N, Bunting P. The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. BJU Int 2002 May; 89(7):703-9.
    View PubMed
  45. Choo R, Sandler H, Warde P, Hruby G, DeBoer G. Survey of radiation oncologists: practice patterns of the management of stage I seminoma of testis in Canada and a selected group in the United States. Can J Urol 2002 Apr; 9(2):1479-85.
    View PubMed
  46. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, Fleshner N, Bunting P, Hruby G. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002 Apr; 167(4):1664-9.
    View PubMed
  47. Choo R, Hruby G, Hong J, Hong E, DeBoer G, Danjoux C, Morton G, Klotz L, Bhak E, Flavin A. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not? Int J Radiat Oncol Biol Phys 2002 Mar 1; 52(3):674-80.
    View PubMed
  48. Do V, Choo R, DeBoer G, Klotz L, Danjoux C, Morton G, Rakovitch E, Szumacher E, Fleshner N, Hruby G, Bunting P. The role of serial free/total prostate specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. Br J Urol Int 2002; 89:703-9.
    View PubMed
  49. Do V, Choo R, DeBoer G, Herschorn S, Danjoux C, Cheng C, Barak I. Urodynamic findings at 3 months post-radiotherapy in patients treated with conformal external beam radiotherapy for prostate carcinoma. Br J Urol Int 2002; 90:62-7.
    View PubMed
  50. Grimaldi J, Fleshner N, DeBoer G, Choo R, Klotz L. Outcomes of 200 patients with localized prostate cancer enrolled in a watchful waiting protocol. UroOncology 2002; 2:93-4.
    View PubMed
  51. Lock M, Loblaw DA, Choo R, Imrie K. Disseminated intravascular coagulation and PC-SPES: a case report and literature review. Can J Urol 2001 Aug; 8(4):1326-9.
    View PubMed
  52. Choo R, DeBoer G, Klotz L, Danjoux C, Morton GC, Rakovitch E, Fleshner N, Bunting P, Kapusta L, Hruby G. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001 Jul 1; 50(3):615-20.
    View PubMed
  53. Hruby G, Choo R, Klotz L, Danjoux C, Murphy J, Deboer G, Morton G, Rakovitch E, Szumacher E, Fleshner N. The role of serial transrectal ultrasonography in a 'watchful waiting' protocol for men with localized prostate cancer. BJU Int 2001 May; 87(7):643-7.
    View PubMed
  54. Crook J, Lukka H, Klotz L, Bestic N, Johnston M, Genitourinary Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. CMAJ 2001 Apr 3; 164(7):975-81.
    View PubMed
  55. Crook J, Lukka H, Klotz L, Bestic N, Johnston M, Genitourinary Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. Systemic overview of the evidence for brachytherapy in clinically localized prostate cancer. CMAJ 2001 Apr 3; 164(7):975-81.
    View PubMed
  56. Hruby G, Choo R, Lehman M, Herschorn S, Kapusta L. Female clear cell adenocarcinoma arising within a urethral diverticulum. Can J Urol 2000 Dec; 7(6):1160-3.
    View PubMed
  57. Choo CR, Danjoux C, Morton G. Should pathological T3 and/or margin positive prostate cancer receive adjuvant therapy? A radiation oncologist’s view. Can J Urol 2000; 7:1043-50.
    View PubMed
  58. MacKenzie R, Balogh J, Choo R, Franssen E. Accelerated radiotherapy with delayed concomitant boost in locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1999 Oct 1; 45(3):589-95.
    View PubMed
  59. Nam RK, Fleshner N, Rakovitch E, Klotz L, Trachtenberg J, Choo R, Morton G, Danjoux C. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol 1999 May; 161(5):1521-4.
    View PubMed
  60. Iscoe NA, Bruera E, Choo RC. Prostate cancer: 10. Palliative care. CMAJ 1999 Feb 9; 160(3):365-71.
    View PubMed
  61. International collaboration of trialists on behalf of the Medical Research Council Advanced Bladder Working Party, EORTC Genito-Urinary Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, N Neoadjuvant cisplatin, methotrexate, vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial. Lancet 1999; 354:533-540.
    View PubMed
  62. Flavin A, Choo R, Franssen E, Danjoux C, Morton G. Pathological T3 and/or margin positive prostate adenocarcinoma with undetectable postoperative PSA - to irradiate or not?: analysis of freedom from PSA failure. Can J Urol 1998 Jun; 5(2):544-550.
    View PubMed
  63. Choo R, Flavin A, Danjoux CE, Klotz LH. Can radiotherapy salvage isolated local recurrence following radical prostatectomy? Can J Urol 1997 Sep; 4(3):395-399.
    View PubMed
  64. Danjoux CE, DeBoer G, Choo RC, Iscoe NA, Morton GC, Young CS, Bjarnason GA, Klotz LH. Survey of consecutive prostate cancer patients attending the Toronto Sunnybrook Regional Cancer Centre (TSRCC). Can J Urol 1996 Nov; 3(4):268-276.
    View PubMed
  65. Choo R, Grimard L, Esche B, Crook J, Genest P, Odell P. Brachytherapy of neck metastases. J Otolaryngol 1993 Feb; 22(1):54-7.
    View PubMed
  66. Choo R, Grimard L, Esche B, Crook J, Genest P. Brachytherapy of neck metastases. J Otolaryngol 1993; 22:54-7.
    View PubMed
  67. Choo R, Tannock I. Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the Princess Margaret Hospital experience. Cancer 1991 Nov 15; 68(10):2120-4.
    View PubMed


Appointments Contact Us Make A Gift Search

Legal restrictions and terms of use applicable to this site

Use of this site signifies your agreement to the terms of use
Copyright © 2009 Mayo Foundation for Medical Education and Research.